ClinicalTrials.gg
CompletedNCT07223671Updated Mar 27, 2026

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

A Phase 1 interventional study of Repotrectinib and Metformin in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug-Drug Interactions
  • Pharmacokinetics
  • Transporter Probe Substrates
  • CYP P450 Probe Substrates
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a (BMI) of 18.0 to 32.0 kg/m2 and should be between the ages of 18-60 years inclusive.
  • Healthy female (as assigned at birth) participants who are individuals not of (INOCBP) and healthy males with no deviation from normal for the following: medical history, physical examination, vital signs, 12-lead , and clinical laboratory assessment results as determined by the investigator.

Exclusion criteria

Exclusion Criteria

  • Participants must not have a significant history of clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric, neoplastic, or genitourinary abnormalities/diseases as determined by the investigator or designee.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: Repotrectinib · Drug: Metformin · Drug: Digoxin · Drug: Rosuvastatin

  • Experimental
    Cohort 2

    Drug: Repotrectinib · Drug: Bupropion · Drug: Flurbiprofen · Drug: Omeprazole

Interventions

  • Specified dose on specified days

  • DrugMetformin

    Specified dose on specified days

  • DrugDigoxin

    Specified dose on specified days

  • DrugRosuvastatin

    Specified dose on specified days

  • DrugBupropion

    Specified dose on specified days

  • Specified dose on specified days

  • DrugOmeprazole

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin.

    Time frame: Up to approximately Day 17 post dose

  2. Cohort 1: AUC (0-T) of Probe Substrate Without Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin.

    Time frame: Up to approximately Day 17 post dose

  3. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin.

    Time frame: Up to approximately Day 17 post dose

  4. Cohort 1: AUC(INF) of Probe Substrate Without Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin.

    Time frame: Up to approximately Day 17 post dose

  5. Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin

    Time frame: Up to approximately Day 17 post dose

  6. Cohort 1: Cmax of Probe Substrate Without Repotrectinib

    Probe substrate contains metformin, digoxin, and rosuvastatin

    Time frame: Up to approximately Day 17 post dose

  7. Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With Repotrectinib

    Time frame: Up to approximately Day 17 post dose

  8. Cohort 1: AUC (0-48) of Metformin Without Repotrectinib

    Time frame: Up to approximately Day 17 post dose

  9. Cohort 1: Renal Clearance (CLR) of Metformin in Urine

    Time frame: Up to approximately Day 16 post dose

  10. Cohort 2: AUC (0-T) of Probe Substrate With Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

  11. Cohort 2: AUC (0-T) of Probe Substrate Without Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

  12. Cohort 2: AUC (INF) of Probe Substrate With Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

  13. Cohort 2: AUC (INF) of Probe Substrate Without Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

  14. Cohort 2: Cmax of Probe Substrate With Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

  15. Cohort 2: Cmax of Probe Substrate Without Repotrectinib

    Probe substrate contains bupropion, hydroxybupropion, flurbiprofen, 4'-hydroxyflurbiprofen, omeprazole, 5'- hydroxyomeprazole)

    Time frame: Up to approximately Day 17 post dose

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Up to approximately Day 45 post dose

  2. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to approximately Day 45 post dose

  3. Number of Participants With Clinically Significant Physical Examination Findings

    Time frame: Up to approximately Day 17 post dose

  4. Number of Participants With Clinically Significant Vital Sign Measurements

    Time frame: Up to approximately Day 17 post dose

  5. Number of Participants With Clinically Significant 12-lead Electrocardiogram (12-lead ECG) Findings

    Time frame: Up to approximately Day 17 post dose

  6. Number of Participants With Clinically Significant Safety Laboratory Test Results

    Time frame: Up to approximately Day 17 post dose

07

Study locations

1 site
  • Local Institution - 0001
    Daytona Beach, Florida 32117-5116, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Feb 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 3, 2025
StartActual
Dec 31, 2025
Primary completionActual
Feb 19, 2026
CompletionActual
Mar 19, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223671
Responsible party
Sponsor
First posted
Nov 3, 2025
Start date
Dec 31, 2025
Primary completion
Feb 19, 2026
Completion
Mar 19, 2026
Last update
Mar 27, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repotrectinib

Start the discussion